BIOMAT Database Logo BIOMAT Database Logo

Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects. 1990

R M Bukowski, and S Murthy, and J Sergi, and G T Budd, and S McKeever, and S V Medendorp, and R Tubbs, and V Gibson, and J Finke
Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Ohio 44195-5236.

A phase I trial of high-dose continuous infusion rIL-2 over 5 days and i.m. recombinant human interferon-alpha (rHuIFN-alpha 2a) three times weekly in 23 patients with advanced malignancy has been completed. Cohorts of patients were treated at three different dose levels: rIL-2 3.0 x 10(6) u/m2 plus rHuIFN-alpha 2a either 5.0 or 10.0 x 10(6) u/m2, and rIL-2 4.5 x 10(6) u/m2 plus rHuIFN-alpha 2a 5.0 x 10(6) u/m2 over 4 weeks. Dose-limiting toxicity consisted of pulmonary and neurologic side effects, and the maximal tolerated dose was 3.0 x 10(6) u/m2 on days 1-5 or rIL-2, and 10.0 x 10(6) u/m2 three times weekly of rHuIFN-alpha 2a. Four partial responses (renal carcinoma, three; endometrial carcinoma, one) were seen. In conclusion, toxicity of this schedule of rIL-2 and rHuIFN-alpha 2a was significant, but manageable. Further investigation is needed to define the antitumor activity of this combination.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009420 Nervous System The entire nerve apparatus, composed of a central part, the brain and spinal cord, and a peripheral part, the cranial and spinal nerves, autonomic ganglia, and plexuses. (Stedman, 26th ed) Nervous Systems,System, Nervous,Systems, Nervous
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz

Related Publications

R M Bukowski, and S Murthy, and J Sergi, and G T Budd, and S McKeever, and S V Medendorp, and R Tubbs, and V Gibson, and J Finke
Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
November 1989, Cancer research,
R M Bukowski, and S Murthy, and J Sergi, and G T Budd, and S McKeever, and S V Medendorp, and R Tubbs, and V Gibson, and J Finke
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a.
April 1993, Cancer,
R M Bukowski, and S Murthy, and J Sergi, and G T Budd, and S McKeever, and S V Medendorp, and R Tubbs, and V Gibson, and J Finke
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.
November 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R M Bukowski, and S Murthy, and J Sergi, and G T Budd, and S McKeever, and S V Medendorp, and R Tubbs, and V Gibson, and J Finke
A phase I trial of 5-day continuous infusion cisplatin and interferon alpha.
January 1995, Cancer chemotherapy and pharmacology,
R M Bukowski, and S Murthy, and J Sergi, and G T Budd, and S McKeever, and S V Medendorp, and R Tubbs, and V Gibson, and J Finke
Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.
January 1989, Cancer investigation,
R M Bukowski, and S Murthy, and J Sergi, and G T Budd, and S McKeever, and S V Medendorp, and R Tubbs, and V Gibson, and J Finke
A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum.
February 1991, Investigational new drugs,
R M Bukowski, and S Murthy, and J Sergi, and G T Budd, and S McKeever, and S V Medendorp, and R Tubbs, and V Gibson, and J Finke
Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
February 1993, Cancer,
R M Bukowski, and S Murthy, and J Sergi, and G T Budd, and S McKeever, and S V Medendorp, and R Tubbs, and V Gibson, and J Finke
Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer.
November 2004, Investigational new drugs,
R M Bukowski, and S Murthy, and J Sergi, and G T Budd, and S McKeever, and S V Medendorp, and R Tubbs, and V Gibson, and J Finke
Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
April 1989, Journal of biological response modifiers,
R M Bukowski, and S Murthy, and J Sergi, and G T Budd, and S McKeever, and S V Medendorp, and R Tubbs, and V Gibson, and J Finke
Clinical application of continuous infusion of recombinant interleukin-2.
January 1989, European journal of cancer & clinical oncology,
Copied contents to your clipboard!